DUBLIN--(BUSINESS WIRE)--The "Notch Signaling Pathway Inhibitor -Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
'Notch Signaling Pathway Inhibitor - Pipeline Insight, 2018' report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Notch Signaling Pathway Inhibitor development.
Descriptive coverage of pipeline development activities for Notch Signaling Pathway Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Key Topics Covered:
1. Report Introduction
2. Notch Signaling Pathway Inhibitor - Overview
3. Pipeline Therapeutics
- An Overview of Pipeline Products for Notch Signaling Pathway Inhibitor
4. Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
6. Notch Signaling Pathway Inhibitor Pipeline Products in Non-clinical Stages
- Product Description
- Research and Development
-
Product Development Activities
7. Therapeutic Assessment: Active Products
- Pipeline Assessment by Route of Administration
- Pipeline Assessment by Stage and Route of Administration
- Pipeline Assessment by Molecule Type
- Pipeline Assessment by Stage and Molecule Type
8. Inactive Pipeline Products
- Product Description
- Research and Development
- Product Development Activities
-
Reason for dormancy/discontinuation
Companies Mentioned
- Bristol-Myers Squibb
- Eli Lilly
- OncoMed
- University of Wisconsin
- MedImmune
- Merck/ Cancer research UK
- Pfizer
- Roche/ US National Cancer Institute
- Merck
- Interprotein Corporation